Lung Transplant Week

HomePatientsLung Disease Week at the ATS2016 ▶ Lung Transplant Week
Lung Transplant Week

Lung Transplant Week

Welcome Message

Together with the Lung Transplant Foundation, we would like to welcome you to Lung Transplant week at the ATS.

It is our pleasure to provide information to you about this complex but important therapy for individuals who have chronic and progressive lung disease.

Despite the development of new treatments, we still do not have cures for most chronic lung diseases including COPD, IPF, Cystic Fibrosis and Pulmonary Hypertension.  Therefore, lung transplantation remains an important therapy for chronic and progressive  lung disease.   The number of lung transplant procedures has continued to climb over the last 3 decades.  Based on the latest report from the International Society for Heart and Lung Transplantation, there were over 4,000 lung transplants performed in 2013 – this number has nearly doubled over the last 10 years.  This increase is due to both a higher burden of lung disease worldwide as well as an improvement in transplant awareness for donors, patients and physicians.

While the long-term survival from lung transplantation remains a challenge, the short and medium-term outcomes are very good, with median 1-year survival of 86% and 3 year survival of 66%.  Long-term survival is limited mostly by Chronic Lung Allograft Dysfunction (CLAD).  This entity, which has a few different presentations, is poorly understood.  Currently there are no known therapies for CLAD.  The ATS and Lung Transplant Foundation are working hard to support research to better understand ways to improve long-term survival and quality of life following lung transplantation.

We hope that Lung Transplant Week at the American Thoracic Society will help increase the public recognition of this treatment, which will continue to advance ongoing research and drug development.


Carolyn Calfee, MD

Carolyn Calfee, MD
Associate Professor, Pulmonary and Critical Care Medicine
University of California, San Francisco
Member, ATS Board of Directors

Jeff Goldstein

Jeff Goldstein
President, Lung Transplant Foundation
Member, ATS Public Advisory Roundtable

Steven Hays

Steven Hays, MD
Medical Director, Associate Professor of Medicine
Member, ATS




In June 2009, the national Lung Transplant Foundation (LTF) was founded as a non-profit organization by a group of lung transplant recipients from Durham and Chapel Hill, NC. These recipients from Duke University and UNC Hospitals realized promotion and funding of research to improve the post lung transplant experience and long term outcomes was severely lacking, so they created the LTF to tackle one of the most difficult and life-threatening issues facing transplant recipients, chronic rejection or bronchiolitis obliterans syndrome (BOS).